fda approved weight loss drugs
The FDA has approved a new weight loss drug intended for those obese persons who have failed at other weight loss options. It says the drug is to be used along with a lower calorie intake and increased physical activity. The drug is called Saxenda and it A view of a company flag at the global healthcare company Novo Nordisk’s factory in Chartres, France, on February 17, 2014. JEAN-FRANCOIS MONIER/AFP/Getty Images A new, injectable weight-loss drug has been approved by the U.S. Food and Drug Administration. The U.S. Food and Drug Administration today approved Saxenda (liraglutide [rDNA origin] injection enrolled patients without diabetes showed that patients had an average weight loss of 4.5 percent from baseline compared to treatment with a placebo KIRKSVILLE, MO — Just a few weeks ago, we learned of a new pill approved by the FDA for weight loss. Last week, another drug, saxenda, was approved as well. Dr. Justin Puckett, a board certified weight loss specialist, joined us this morning to talk about it. Just in time for those New Year’s weight loss resolutions, the Food and Drug Administration (FDA) has approved a new weight loss drug. However, Saxenda (liraglutide) requires an injection and is recommended for specific categories of individuals After promising clinical trials, the Food and Drug Administration (FDA) has approved a drug called Saxenda for chronic weight management that will be available by prescription to overweight and obese adults. Intended to accompany a diet and exercise plan .
Just in time for all those weight-loss New Year’s resolutions, the Food and Drug Administration (FDA) has approved another new weight management treatment. Saxenda is an injection that, when combined with a reduced-calorie diet and physical activity The FDA has approved three weight loss pills in recent years. It cleared Vivus Inc.’s Qsymia and Arena Pharmaceuticals Inc.’s Belviq in 2012 and granted approval to Orexigen Therapeutics Inc.’s drug Contrave in September. While analysts initially expected Novo Nordisk (NYSE: NVO ) on Tuesday gained Food and Drug Administration approval for its obesity drug Saxenda but with placebo-adjusted weight loss of about 4.5%, it’s hard to see a major shift away from the oral drugs. The weight loss is better could be patient resistance to the injectable nature of the medicine when there are three additional drugs approved by the FDA for weight loss that are taken orally: Belviq, Qsymia and Contrave. Those drugs, though, all carry the potential risk for .
fda approved weight loss drugs Pictures